The Blood Pressure and Metabolic Effects of Nebivolol in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose - Full Text View

Sponsor:	Forest Laboratories
Information provided by:	Forest Laboratories
ClinicalTrials.gov Identifier:	NCT00673790

Purpose

This study is being done to see if the blood pressure and metabolic effects of an approved drug nebivolol is comparable to that of another approved drug hydrochlorothiazide (HCTZ) and placebo in hypertensive patients.

Condition	Intervention	Phase
Hypertension	Drug: Nebivolol Drug: HCTZ Drug: Placebo	Phase IV

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study
Official Title:	Blood Pressure and Metabolic Effects of Nebivolol Compared With Hydrochlorothiazide and Placebo in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose

Resource links provided by NLM:

MedlinePlus related topics: High Blood Pressure

Drug Information available for: Hydrochlorothiazide Dextrose Nebivolol

U.S. FDA Resources

Further study details as provided by Forest Laboratories:

Primary Outcome Measures:

Trough seated diastolic blood pressure (DBP) [ Time Frame: Change from Baseline To Week 12 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Plasma glucose level after an oral glucose tolerance test [ Time Frame: Change from Baseline To Week 12 ] [ Designated as safety issue: No ]
Homeostasis Model Assessment of Insulin Resistance [ Time Frame: Change from Baseline To Week 12 ] [ Designated as safety issue: No ]
Trough seated systolic blood pressure (SBP) [ Time Frame: Change from Baseline To Week 12 ] [ Designated as safety issue: No ]
Fasting Blood Glucose [ Time Frame: Change from Baseline To Week 12 ] [ Designated as safety issue: No ]

Estimated Enrollment:	500
Study Start Date:	May 2008
Estimated Primary Completion Date:	July 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Active Comparator Nebivolol	Drug: Nebivolol Encapsulated Nebivolol 5 mg, 10 mg, 20, mg, 40 mg total daily dosage, oral administration
2: Active Comparator HCTZ	Drug: HCTZ Encapsulated Hydrochlorothiazide 12.5 mg or 25 mg total daily dosage, oral administration.
3: Placebo Comparator Placebo	Drug: Placebo Placebo

Detailed Description:

This study is double blind (neither you nor the physician will know when you are receiving placebo, which is an inactive compound such as a sugar pill, or active study drugs nebivolol or hydrochlorothiazide).

All participants will also receive lisinopril, an angiotensin converting enzyme, or losartan, an angiotensin receptor blocker. All medications are approved and marketed for the treatment of hypertension.This study is being conducted in about 500 patients at approximately 80 research centers in the United States.

The study consists of approximately 9 study visits over a period of 5 months. During these visits, patients will undergo routine health exams and some special laboratory tests such as an oral glucose tolerance test.

Eligibility

Ages Eligible for Study:	18 Years to 80 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Male or female, ambulatory outpatients 18-80 years old at screening.
Have a history of hypertension and taking up to 2 medications for high blood pressure.
Qualifying laboratory results confirming impaired fasting glucose or impaired glucose tolerance
Vision and hearing (hearing aid permissible) sufficient for compliance with questionnaire completion

Exclusion Criteria:

Have clinically significant respiratory, liver or cardiovascular disease
Presence of coronary artery disease requiring treatment with a beat blocker, calcium channel blocker or nitrates
Use of niacin or antidiabetic drugs (oral or injectable) within 6 months before study entry
Have a history of hypersensitivity to nebivolol, other beta-blockers, hydrochlorothiazide, or other sulfonamide-derived drugs.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00673790

Contacts

Contact: Sandra Beaird, PharmD

800/678/1605 ext 66297

info@forestpharm.com

Show 105 Study Locations

Sponsors and Collaborators

Forest Laboratories

Investigators

Study Director:

Kati Gutierrez, PharmD, PhD

Forest Research Institute, a subdisiary of Forest Laboratories, Inc.

More Information

No publications provided

Responsible Party:	Forest Research Institute, a subsidiary of Forest Laboratories Inc. ( John Whalen, MD, Executive Director, Clinical Development, Cardiovascular )
Study ID Numbers:	NEB-MD-04
Study First Received:	April 29, 2008
Last Updated:	October 28, 2009
ClinicalTrials.gov Identifier:	NCT00673790 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Forest Laboratories:

nebivolol
BYSTOLIC ™
hydrochlorothiazide
lisinopril
Prinivil (TM)
Zestril (TM)

losartan
Cozaar (TM)
Impaired Fasting Glucose
Impaired Glucose Tolerance
hypertension

Additional relevant MeSH terms:

Neurotransmitter Agents
Vasodilator Agents
Adrenergic Agents
Molecular Mechanisms of Pharmacological Action
Diuretics
Physiological Effects of Drugs
Sodium Chloride Symporter Inhibitors
Prediabetic State
Membrane Transport Modulators
Hyperglycemia
Therapeutic Uses
Adrenergic beta-Antagonists
Cardiovascular Diseases
Metabolic Diseases

Glucose Intolerance
Diabetes Mellitus
Vascular Diseases
Nebivolol
Endocrine System Diseases
Cardiovascular Agents
Antihypertensive Agents
Hydrochlorothiazide
Pharmacologic Actions
Natriuretic Agents
Adrenergic Antagonists
Glucose Metabolism Disorders
Hypertension

ClinicalTrials.gov processed this record on November 27, 2009